SynProtX: a large-scale proteomics-based deep learning model for predicting synergistic anticancer drug combinations
GigaScience · 2025
DOI: 10.1093/gigascience/giaf080 ↗Kurz gefasst
Fachartikel in der Zeitschrift GigaScience, 2025. Verfasst von Bundit Boonyarit und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Information Science and Technology, Vidyasirimedhi Institute of Science and Technology, Rayong 21210, Thailand. Hauptthemen laut MEDLINE: Deep Learning, Proteomics, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vidyasirimedhi Institute of Science and Technology.
Abstract (Originalsprache)
Motivation Drug combination therapy plays a pivotal role in addressing the molecular heterogeneity of cancer, improving treatment efficacy, minimizing resistance, and reducing toxicity. Deep learning approaches have significantly advanced drug combination discovery by addressing the limitations of conventional laboratory experiments, which are time-consuming and costly. While most existing models rely on the molecular structure of drugs and gene expression data, incorporating protein-level expression provides a more accurate representation of cellular behavior and drug responses. In this study, we introduce SynProtX, an enhanced deep learning model that explicitly integrates large-scale proteomics with deep neural networks (DNNs) and the molecular structure of drugs with graph neural networks (GNNs). Results The SynProtX-GATFP model, which combines molecular graphs and fingerprints through a graph attention network architecture, demonstrated superior predictive performance for the FRIEDMAN study dataset. We further evaluated its cell line–specific performance, which achieved accuracy across diverse tissue and study datasets. By incorporating protein expression data, the model consistently enhanced predictive performance over gene expression–only models, reflecting the functional state of cancer cells. The generalizability of SynProtX was rigorously validated using cold-start prediction, including leave-drug-combination-out, leave-drug-out, and leave-cell-line-out validation strategies, highlighting its robust performance and potential for clinical applicability. Additionally, SynProtX identified key cancer-associated proteins and molecular substructures, offering novel insights into the biological mechanisms underlying drug synergy. These findings highlight the potential of integrating large-scale proteomics and multiomics data to advance anticancer drug design and combination therapy strategies for personalized medicine. Availability and implementation: https://github.com/manbaritone/SynProtX.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Information Science and Technology, Vidyasirimedhi Institute of Science and Technology, Rayong 21210, Thailand.
- Kamnoetvidya Science Academy, Rayong 21210, Thailand.
- School of Information, Computer, and Communication Technology, Sirindhorn International Institute of Technology, Thammasat University, Pathum Thani 12120, Thailand.
- Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
- Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand.
- Center of Excellence in Structural and Computational Biology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
ORCID-Profile: Bundit Boonyarit, Matin Kositchutima, Tisorn Na Phattalung, Nattawin Yamprasert, Chanitra Thuwajit, Thanyada Rungrotmongkol, Sarana Nutanong
Förderung
- Vidyasirimedhi Institute of Science and Technology
Zitieren
APA
Boonyarit, B., Kositchutima, M., Phattalung, T. N., Yamprasert, N., Thuwajit, C., Rungrotmongkol, T., & Nutanong, S. (2025). SynProtX: a large-scale proteomics-based deep learning model for predicting synergistic anticancer drug combinations. GigaScience. https://doi.org/10.1093/gigascience/giaf080
Vancouver
Boonyarit B, Kositchutima M, Phattalung TN, Yamprasert N, Thuwajit C, Rungrotmongkol T, et al. SynProtX: a large-scale proteomics-based deep learning model for predicting synergistic anticancer drug combinations. GigaScience. 2025. doi:10.1093/gigascience/giaf080
BibTeX
@article{Boonyarit2025,
author = {Boonyarit, Bundit and Kositchutima, Matin and Phattalung, Tisorn Na and Yamprasert, Nattawin and Thuwajit, Chanitra and Rungrotmongkol, Thanyada and Nutanong, Sarana},
title = {SynProtX: a large-scale proteomics-based deep learning model for predicting synergistic anticancer drug combinations},
journal = {GigaScience},
year = {2025},
doi = {10.1093/gigascience/giaf080}
}
EUVIMED